Diversify Wealth Management LLC Sells 11,099 Shares of Novo Nordisk A/S (NYSE:NVO)

Diversify Wealth Management LLC reduced its position in shares of Novo Nordisk A/S (NYSE:NVO) by 31.0% during the 4th quarter, HoldingsChannel.com reports. The fund owned 24,693 shares of the company’s stock after selling 11,099 shares during the quarter. Diversify Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $2,130,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Hsbc Holdings PLC lifted its stake in Novo Nordisk A/S by 19.4% in the 2nd quarter. Hsbc Holdings PLC now owns 54,804 shares of the company’s stock valued at $7,852,000 after purchasing an additional 8,922 shares during the last quarter. AE Wealth Management LLC lifted its position in shares of Novo Nordisk A/S by 161.5% in the second quarter. AE Wealth Management LLC now owns 19,319 shares of the company’s stock valued at $2,758,000 after buying an additional 11,930 shares during the last quarter. Epoch Investment Partners Inc. boosted its stake in shares of Novo Nordisk A/S by 4.5% during the 2nd quarter. Epoch Investment Partners Inc. now owns 14,132 shares of the company’s stock worth $2,017,000 after acquiring an additional 614 shares during the period. Gabelli Funds LLC increased its holdings in shares of Novo Nordisk A/S by 35.7% during the 2nd quarter. Gabelli Funds LLC now owns 46,963 shares of the company’s stock worth $6,703,000 after acquiring an additional 12,363 shares during the last quarter. Finally, DRW Securities LLC bought a new stake in Novo Nordisk A/S in the 2nd quarter valued at $1,298,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $140.20.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $78.74 on Tuesday. The stock’s fifty day moving average price is $97.76 and its two-hundred day moving average price is $116.89. The firm has a market cap of $353.33 billion, a PE ratio of 25.48, a price-to-earnings-growth ratio of 0.92 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.